Raymond James & Associates Pfizer Inc Transaction History

Raymond James & Associates

$146 Billion
Q1 2024

A detailed history of Raymond James & Associates transactions in Pfizer Inc stock. As of the latest transaction made, Raymond James & Associates holds 8,763,485 shares of PFE stock, worth $245 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

8,763,485

Previous 7,837,525 11.81%

Holding current value

$245 Million

Previous $226 Million 7.78%

% of portfolio

0.17%

Previous 0.17%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	BUY	$25.89 - $29.73 $24 Million - $27.5 Million	925,960 Added 11.81%	8,763,485 $243 Million
Q4 2023 Jan 16, 2024	SELL	$26.13 - $33.94 $20.2 Million - $26.2 Million	-771,857 Reduced 8.97%	7,837,525 $226 Million
Q3 2023 Oct 24, 2023	SELL	$32.09 - $37.51 $4.33 Million - $5.06 Million	-135,019 Reduced 1.54%	8,609,382 $286 Million
Q2 2023 Jul 25, 2023	SELL	$36.12 - $41.79 $3.96 Million - $4.59 Million	-109,770 Reduced 1.24%	8,744,401 $321 Million
Q1 2023 Apr 14, 2023	BUY	$39.39 - $51.28 $12.3 Million - $16 Million	311,509 Added 3.65%	8,854,171 $361 Million

Q4 2022 Feb 08, 2023	BUY	$41.75 - $54.5 $14.6 Million - $19 Million	348,547 Added 4.25%	8,542,662 $438 Million
Q3 2022 Oct 25, 2022	BUY	$43.76 - $53.42 $7.19 Million - $8.77 Million	164,241 Added 2.05%	8,194,115 $359 Million
Q2 2022 Aug 12, 2022	BUY	$46.53 - $55.17 $3.45 Million - $4.09 Million	74,191 Added 0.93%	8,029,874 $421 Million
Q1 2022 May 11, 2022	BUY	$45.75 - $56.69 $24.9 Million - $30.8 Million	543,445 Added 7.33%	7,955,683 $412 Million
Q4 2021 Feb 08, 2022	SELL	$41.32 - $61.25 $6.27 Million - $9.29 Million	-151,716 Reduced 2.01%	7,412,238 $438 Million
Q3 2021 Nov 02, 2021	SELL	$39.25 - $50.42 $45 Million - $57.9 Million	-1,147,412 Reduced 13.17%	7,563,954 $325 Million
Q2 2021 Aug 11, 2021	BUY	$35.91 - $40.68 $20.1 Million - $22.7 Million	558,427 Added 6.85%	8,711,366 $341 Million
Q1 2021 May 14, 2021	SELL	$33.49 - $37.77 $22.1 Million - $24.9 Million	-660,488 Reduced 7.49%	8,152,939 $295 Million
Q4 2020 Feb 12, 2021	SELL	$33.47 - $42.56 $28.6 Million - $36.4 Million	-854,528 Reduced 8.84%	8,813,427 $324 Million
Q3 2020 Nov 04, 2020	SELL	$31.75 - $37.25 $25 Million - $29.3 Million	-786,766 Reduced 7.53%	9,667,955 $355 Million
Q2 2020 Jul 28, 2020	SELL	$30.12 - $36.54 $129 Million - $156 Million	-4,278,478 Reduced 29.04%	10,454,721 $342 Million
Q1 2020 Apr 21, 2020	BUY	$27.03 - $38.62 $8.84 Million - $12.6 Million	327,154 Added 2.27%	14,733,199 $481 Million
Q4 2019 Feb 12, 2020	BUY	$32.92 - $37.36 $60.5 Million - $68.6 Million	1,837,440 Added 14.62%	14,406,045 $564 Million
Q3 2019 Nov 07, 2019	BUY	$32.49 - $42.13 $64.3 Million - $83.4 Million	1,980,253 Added 18.7%	12,568,605 $452 Million
Q2 2019 Aug 06, 2019	BUY	$36.98 - $41.52 $28.5 Million - $32 Million	769,699 Added 7.84%	10,588,352 $459 Million
Q1 2019 May 06, 2019	SELL	$37.5 - $41.2 $12.7 Million - $13.9 Million	-338,238 Reduced 3.33%	9,818,653 $417 Million
Q4 2018 Feb 11, 2019	SELL	$38.47 - $43.86 $28.3 Million - $32.2 Million	-734,402 Reduced 6.74%	10,156,891 $443 Million
Q3 2018 Nov 14, 2018	BUY	$34.47 - $41.81 $11.5 Million - $14 Million	334,410 Added 3.17%	10,891,293 $480 Million
Q2 2018 Aug 14, 2018	BUY	$32.98 - $35.16 $31 Million - $33.1 Million	940,153 Added 9.78%	10,556,883 $383 Million
Q1 2018 May 14, 2018	BUY	$31.91 - $37.02 $12.8 Million - $14.9 Million	401,662 Added 4.36%	9,616,730 $341 Million
Q4 2017 Feb 14, 2018	BUY	$33.26 - $35.29 $12.1 Million - $12.8 Million	363,546 Added 4.11%	9,215,068 $334 Million
Q3 2017 Nov 13, 2017	BUY	$31.0 - $34.15 $10.3 Million - $11.3 Million	331,993 Added 3.9%	8,851,522 $316 Million
Q2 2017 Aug 14, 2017	BUY	N/A	8,519,529	8,519,529 $286 Million

Others Institutions Holding PFE

# of Institutions

3,159

Shares Held

3.68B

Call Options Held

67.4M

Put Options Held

113M

View Full List

About PFIZER INC

Ticker PFE
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 5,612,349,952
Market Cap $157B
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...

More about PFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Pfizer Inc Transaction History